Making label-free biosensing more accessible to every lab

By Biotech News, May 26, 2026 — Laboratories increasingly rely on label-free technologies to study biomolecular interactions, but high costs, complexity, and limited throughput still restrict widespread adoption.

Delta Life Science addresses this challenge by developing accessible biosensing solutions that combine ease of use with reliable interaction analysis. The inQuiQ platform leverages integrated photonics to simplify system design and operation, enabling researchers to generate binding data without extensive training.

The system supports a wide range of applications, including antibody development, fragment-based screening, nucleic acid interactions, and membrane protein research. In these areas, the ability to rapidly generate and compare binding data is critical for decision-making. By reducing barriers to entry, inQuiQ allows more laboratories to integrate label-free analysis into earlier stages of their workflows.

Compared to traditional techniques such as Surface Plasmon Resonance, inQuiQ offers a more accessible approach while maintaining the performance for meaningful interaction analysis. This balance between usability and data quality makes it suitable for both exploratory research and more advanced studies.

The recently launched inQuiQ768 expands these capabilities by enabling automatic analysis of up to 768 samples. Researchers can run more conditions and replicates within a single experiment, improving data robustness without increasing operational complexity.

Already adopted by a growing number of research institutions and industrial laboratories, inQuiQ supports faster decision-making and broadens access to advanced biomolecular interaction analysis.